SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company, has announced the presentation of clinical data supporting their investigational drug, rademikibart, at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress. The data, which demonstrates rademikibart's potential to significantly improve lung function and reduce annualized exacerbations in patients with eosinophilic-driven type 2 asthma, will be available from June 13-16, 2025, in Glasgow, United Kingdom, and virtually. These findings support ongoing Phase 2 acute exacerbation studies in asthma and chronic obstructive pulmonary disease (COPD), with topline data expected in the first half of 2026. Presentations are accessible on Connect Biopharma's website under the presentations and publications section.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。